Purpose / DescriptionThis phase 3b, open-label trial examined the safety and efficacy of glecaprevir-pibrentasvir in treatment-naïve and treatment-experienced adults with HCV genotype 5 or 6. The duration of treatment was 8 weeks in participants without cirrhosis (n=75) and 12 weeks in those with compensated cirrhosis (n=9). Overall, 97.6% (82 of 84) individuals enrolled achieved an SVR12; treatment success occurred in 96% of participants with HCV genotype 5 and 98% in those with HCV genotype 6. High efficacy was noted across 14 different HCV genotype 6 subtypes.